Related Experiment Video

Updated: Mar 22, 2026

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

8.0K

Glutathione S-transferase M1 polymorphisms and Parkinson's disease risk: a meta-analysis

Dan Wang1,2, Jun-Xia Zhai3, Dian-Wu Liu1

  • 1a Department of Epidemiology and Biostatistics, School of Public Health , Hebei Medical University , Shijiazhuang , China.

Neurological Research
|April 15, 2016
PubMed
Abstract

Insights

This meta-analysis found no significant link between the glutathione S-transferase M1 (GSTM1) null genotype and Parkinson's disease (PD) risk. The study analyzed 23 publications, concluding that GSTM1 polymorphisms do not appear to influence PD development.

Area of Science:

  • Neuroscience
  • Genetics
  • Epidemiology

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology.
  • Glutathione S-transferase M1 (GSTM1) gene polymorphisms have been investigated as potential risk factors for PD.
  • Previous studies on the association between GSTM1 polymorphisms and PD risk have yielded inconsistent findings.

Purpose of the Study:

  • To clarify the association between glutathione S-transferase M1 (GSTM1) polymorphisms and the risk of developing Parkinson's disease (PD).
  • To conduct a meta-analysis of existing studies to provide a more definitive conclusion on this genetic association.

Main Methods:

  • A comprehensive search of electronic databases was conducted to identify relevant publications.
  • Studies were included based on predefined eligibility criteria.
  • The association was assessed using odds ratios (ORs) and 95% confidence intervals (CIs) within a recessive genetic model (GSTM1 null genotype vs. present genotype).
  • Subgroup analyses were performed based on ethnicity and OR type.

Main Results:

  • A total of 22 publications, comprising 23 studies, were included in the meta-analysis.
  • The overall analysis revealed no significant association between the GSTM1 null genotype and PD risk (ORrandom-effects = 1.06, 95% CI = 0.95-1.19).
  • Subgroup analyses by ethnicity (Caucasians, Asians, Latinos) and OR type (crude vs. adjusted) also showed no significant associations. No publication bias was detected.

Conclusions:

  • The findings from this meta-analysis indicate that the GSTM1 null genotype is not significantly associated with an increased risk of Parkinson's disease.
  • This study contributes to resolving inconsistencies in previous research regarding the role of GSTM1 polymorphisms in PD pathogenesis.
Keywords:
Glutathione S-transferase M1 (GSTM1)Meta-analysisNeurodegenerative movement disorderParkinson’s disease (PD)Polymorphism

More Related Videos

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

15.3K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
58
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
65
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
105
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
1.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K